XML 68 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Share capital (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement, Recognized Amount [Abstract]  
Schedule of Share Capital
Share capital is composed as follows:
Issued and outstanding
Number of shares
December 31,
 20242023
Ordinary shares no par value108,516,819 107,075,754 
Schedule of Fair Value Assumptions Used for All Equity Based Awards Estimated Using Black-Scholes Option Pricing Model
Year ended December 31,
 202420232022
Stock Option Plans
Expected term (years)
5.50-5.73
5.50-6.00
5.33-5.83
Expected volatility
71%-73%
63%-70%
60%-62%
Risk-free interest rate
3.88%-4.43%
3.48%-4.79%
1.58%-4.23%
Dividend yield0.00 %0.00 %0.00 %
ESPP
Expected term (years)0.500.500.50
Expected volatility
73%-90%
56%-122%
51%-77%
Risk-free interest rate
5.13%-5.23%
4.76%-5.38%
0.19%-2.52%
Dividend yield0.00 %0.00 %0.00 %
Schedule of Stock Options to Purchase Ordinary Shares
A summary of the status of the Company’s options to purchase ordinary shares as of December 31, 2024 and changes during the year ended on that date is presented below:
Year ended December 31, 2024
 
Number of
options
Weighted
average
exercise
price
Aggregate
intrinsic
value
Outstanding at beginning of year8,539,507 $40.07 
Granted3,934,564 15.91 
Exercised(235,404)9.16 
Forfeited and cancelled(923,199)51.18 
Outstanding at end of year11,315,468 $31.41 $113,849 
Exercisable options6,739,295 $34.68 $60,993 
Schedule of RSUs and PSUs
A summary of the status of the Company’s RSUs and PSUs as of December 31, 2024 and changes during the year ended on that date is presented below:
 
Year ended December 31, 2024
 Number of
RSUs/PSUs
Weighted
average
grant date
fair value
price
Aggregate
intrinsic
value
Unvested at beginning of year5,813,066 $60.52 
Granted9,655,987 15.43 
Vested(893,876)74.88 
Forfeited and cancelled(2,508,662)42.14 
Unvested at end of year (1)12,066,515 $27.19 $359,582 
(1)    Includes PSUs that have a mix of service, market and other milestone performance vesting conditions which are vested upon achievements of market and performance conditions which are not probable, as of December 31, 2024, in accordance with ASC 718 as follows:

December 31, 2024
Number of
PSUs		Fair value at grant date per PSUTotal fair value at grant date
704,493 $16.30 $11,483 
21,653 19.44 421 
901,284 48.16 43,406 
92,241 76.97 7,100 
234,512 $80.59 $18,899 
15,210 87.66 1,333 
1,969,393 $82,642 
Schedule of Equity-Based Compensation Expenses Related to Company's Equity-Based Awards
The total equity-based compensation expense related to all of the Company’s equity incentive plans recognized for the years ended December 31, 2024, 2023 and 2022, was comprised as follows:
Year ended December 31,
 202420232022
Cost of revenues$6,873 $6,587 $4,690 
Research, development and clinical studies32,716 31,827 30,790 
Sales and marketing43,097 35,968 28,826 
General and administrative77,349 41,226 42,649 
Total share-based compensation expense$160,035 $115,608 $106,955 
Schedule of Stock Option Outstanding
Options outstanding as of December 31, 2024 are as follows:
Exercise price
Number
of options
outstanding
Weighted
average
remaining
contractual
term
Number
of options
exercisable
Weighted
average
remaining
contractual
term
$ (years) (years)
0.00 - 10.00
316,030 2.05316,030 2.05
10.01 - 20.00
5,929,168 6.302,395,159 2.13
20.01 - 30.00
1,744,869 3.401,494,664 2.38
30.01 - 40.00
331,187 5.32241,091 4.10
40.01 - 60.00
1,008,600 4.481,008,600 4.48
60.01 - 100.00
1,688,548 6.851,051,806 6.24
100.01 - 160.00
287,804 6.19223,124 6.17
160.01 - 220.00
9,262 6.428,821 6.42
 11,315,468 5.626,739,295 3.38